RECOVERY (Tocilizumab)
Tocilizumab in COVID-19
Doente / População Intervenção / Exposição Comparação Desfecho
In 4,116 hospitalised hypoxic patients with COVID-19 and inflammation, tocilizumab reduced 28-day mortality compared with usual care.
N
4116
Desenho
Adaptive platform RCT, UK
Desfecho
28-day all-cause mortality
Relevância
2
Resultado31% vs 35% (RR 0.85). Combined with dexamethasone in most patients.
RECOVERY Collaborative Group. Lancet. 2021;397(10285):1637-1645. 10.1016/S0140-6736(21)00676-0
Discussão e crítica
Confirmed REMAP-CAP signal; add tocilizumab in rapidly worsening, CRP-high patients on steroids.